6622 — Zhaoke Ophthalmology Share Price
- HK$748.21m
- -HK$482.75m
- CNY18.75m
- 24
- 27
- 32
- 13
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.34 | ||
Price to Tang. Book | 0.43 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 12.23 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -10.55% | ||
Return on Equity | -10.65% | ||
Operating Margin | -380.94% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CNYm | n/a | n/a | n/a | n/a | 18.75 | 92.96 | 247.9 | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Zhaoke Ophthalmology Ltd is a China-based investment holding company principally engaged in the development, manufacturing and marketing of ophthalmic drugs. The Company’s products include innovative drugs and generic drugs. The Company ‘s products are mainly applied in five ophthalmic indications, including dry eye disease (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- April 29th, 2020
- Public Since
- April 29th, 2021
- No. of Employees
- 297
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Stock Exchange of Hong Kong Limited
- Shares in Issue
- 546,139,172

- Address
- No. 1 Meide 3rd Road, Pearl River, GUANGZHOU
- Web
- https://www.zkoph.com/
- Phone
- +86 2039062888
- Auditors
- KPMG
Upcoming Events for 6622
Similar to 6622
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 23:15 UTC, shares in Zhaoke Ophthalmology are trading at HK$1.37. This share price information is delayed by 15 minutes.
Shares in Zhaoke Ophthalmology last closed at HK$1.37 and the price had moved by -16.46% over the past 365 days. In terms of relative price strength the Zhaoke Ophthalmology share price has underperformed the FTSE Developed Asia Pacific Index by -16.73% over the past year.
The overall consensus recommendation for Zhaoke Ophthalmology is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreZhaoke Ophthalmology does not currently pay a dividend.
Zhaoke Ophthalmology does not currently pay a dividend.
Zhaoke Ophthalmology does not currently pay a dividend.
To buy shares in Zhaoke Ophthalmology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$1.37, shares in Zhaoke Ophthalmology had a market capitalisation of HK$748.21m.
Here are the trading details for Zhaoke Ophthalmology:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6622
Based on an overall assessment of its quality, value and momentum Zhaoke Ophthalmology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Zhaoke Ophthalmology is HK$2.49. That is 81.72% above the last closing price of HK$1.37.
Analysts covering Zhaoke Ophthalmology currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.97 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zhaoke Ophthalmology. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +3.23%.
As of the last closing price of HK$1.37, shares in Zhaoke Ophthalmology were trading -2.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Zhaoke Ophthalmology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$1.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Zhaoke Ophthalmology's directors